Abstract
BackgroundIn recent years, adoptive T cell therapy (ACT) has demonstrated significant effectiveness in treating hematological malignancies. Yet, the clinical benefit in solid tumors is limited and only short-lasting. Although ACT...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
